CA2376596C - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies - Google Patents

Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies Download PDF

Info

Publication number
CA2376596C
CA2376596C CA002376596A CA2376596A CA2376596C CA 2376596 C CA2376596 C CA 2376596C CA 002376596 A CA002376596 A CA 002376596A CA 2376596 A CA2376596 A CA 2376596A CA 2376596 C CA2376596 C CA 2376596C
Authority
CA
Canada
Prior art keywords
antibody
cancer
erbb2
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002376596A
Other languages
English (en)
French (fr)
Other versions
CA2376596A1 (en
Inventor
Camellia W. Adams
Leonard G. Presta
Mark Sliwkowsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2376596(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2376596A1 publication Critical patent/CA2376596A1/en
Application granted granted Critical
Publication of CA2376596C publication Critical patent/CA2376596C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
CA002376596A 1999-06-25 2000-06-23 Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies Expired - Lifetime CA2376596C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
US60/141,316 1999-06-25
PCT/US2000/017366 WO2001000245A2 (en) 1999-06-25 2000-06-23 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Publications (2)

Publication Number Publication Date
CA2376596A1 CA2376596A1 (en) 2001-01-04
CA2376596C true CA2376596C (en) 2009-10-06

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002376596A Expired - Lifetime CA2376596C (en) 1999-06-25 2000-06-23 Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
CA2727172A Abandoned CA2727172A1 (en) 1999-05-26 2000-06-23 Methods of treatment using anti-erbb antibody-maytansinoid conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2727172A Abandoned CA2727172A1 (en) 1999-05-26 2000-06-23 Methods of treatment using anti-erbb antibody-maytansinoid conjugates

Country Status (32)

Country Link
EP (2) EP2112167A3 (cg-RX-API-DMAC7.html)
JP (2) JP4283474B2 (cg-RX-API-DMAC7.html)
KR (2) KR100850389B1 (cg-RX-API-DMAC7.html)
CN (4) CN101518653B (cg-RX-API-DMAC7.html)
AR (1) AR024464A1 (cg-RX-API-DMAC7.html)
AT (2) AT500848B1 (cg-RX-API-DMAC7.html)
AU (2) AU784045B2 (cg-RX-API-DMAC7.html)
BE (1) BE2013C020I2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0012198B8 (cg-RX-API-DMAC7.html)
CA (2) CA2376596C (cg-RX-API-DMAC7.html)
CH (1) CH694589A5 (cg-RX-API-DMAC7.html)
CY (2) CY1109525T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ299702B6 (cg-RX-API-DMAC7.html)
DE (2) DE60042648D1 (cg-RX-API-DMAC7.html)
DK (1) DK1189641T5 (cg-RX-API-DMAC7.html)
ES (1) ES2329437T3 (cg-RX-API-DMAC7.html)
FR (1) FR13C0016I2 (cg-RX-API-DMAC7.html)
GB (1) GB2368796B (cg-RX-API-DMAC7.html)
GE (1) GEP20104998B (cg-RX-API-DMAC7.html)
HU (1) HU226742B1 (cg-RX-API-DMAC7.html)
IL (3) IL146954A0 (cg-RX-API-DMAC7.html)
LU (1) LU92164I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01013458A (cg-RX-API-DMAC7.html)
NO (3) NO328377B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ531426A (cg-RX-API-DMAC7.html)
PL (2) PL204629B1 (cg-RX-API-DMAC7.html)
PT (1) PT1189641E (cg-RX-API-DMAC7.html)
RU (2) RU2270029C2 (cg-RX-API-DMAC7.html)
SI (3) SI2283866T1 (cg-RX-API-DMAC7.html)
TR (1) TR200103756T2 (cg-RX-API-DMAC7.html)
WO (1) WO2001000245A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA200109786B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087260B2 (en) 2013-11-19 2018-10-02 Remegen, Ltd. Anti-HER2 antibody and conjugate thereof

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
KR20020012292A (ko) * 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
BRPI0012198B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc anticorpos humanizados, composição e imunoconjugado
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
GB2397018B (en) * 2001-10-26 2006-05-31 Altarex Medical Corp Combination therapy for treating disease
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2481509A1 (en) * 2002-04-11 2003-10-23 Suzanna Tatarewicz Her-2 receptor tyrosine kinase molecules and uses thereof
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
AU2003273218C1 (en) * 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
PT1530482E (pt) * 2002-07-18 2014-01-15 Helix Biopharma Corp Utilização de urease para inibição de crescimento de células cancerigenas
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004032857A2 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Antibody therapy
EP1613736A4 (en) * 2003-03-11 2007-04-11 Dana Farber Cancer Inst Inc INHIBITION OF VIRUS PATHOGENESIS
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005020923A2 (en) * 2003-08-29 2005-03-10 Cedars-Sinai Medical Center Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
AU2004292933B2 (en) * 2003-11-28 2011-01-06 Glycorex Transplantation Ab Targeting of Erb antigens
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
US20080038271A1 (en) * 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
JP5687822B2 (ja) * 2006-10-12 2015-03-25 中外製薬株式会社 抗ｅｒｅｇ抗体を用いる癌の診断および治療
RU2483080C2 (ru) 2006-10-27 2013-05-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применение
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
KR20160066557A (ko) 2008-03-14 2016-06-10 제넨테크, 인크. 약물 저항성과 관련된 유전적 변이
KR20160125535A (ko) * 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
BRPI1012676A2 (pt) 2009-04-01 2016-04-05 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
CN102361883A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-1/抗-c-Met抗体
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
CA2771086A1 (en) * 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012007760A2 (pt) 2009-10-07 2015-08-25 Macrogenics Inc Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
CA2777825A1 (en) * 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
BR112012010153B1 (pt) 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
CA2788715C (en) * 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2011103242A1 (en) * 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CN103124564B (zh) 2010-03-22 2016-11-09 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
CN119552249A (zh) 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
ES2751381T3 (es) 2010-06-24 2020-03-31 Hoffmann La Roche Composiciones y procedimientos que contienen alquilglucósidos para estabilizar formulaciones que contienen proteínas
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5838221B2 (ja) 2010-12-21 2016-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アイソフォーム濃縮抗体調製物及びこれを得る方法
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
ES2611885T3 (es) 2011-01-31 2017-05-11 Novartis Ag Derivados heterocíclicos novedosos
CN103649326B (zh) * 2011-03-08 2016-08-17 宾夕法尼亚大学理事会 用于治疗和诊断用途的抗体样蛋白
CN103796677B (zh) 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
PT4403228T (pt) 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013078191A1 (en) 2011-11-23 2013-05-30 Medimmune, Llc Binding molecules specific for her3 and uses thereof
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
AU2013214254B2 (en) 2012-01-31 2016-04-21 Novartis Ag Method of treating cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
EP2926142B2 (en) 2012-11-30 2022-07-06 F. Hoffmann-La Roche AG Identification of patients in need of pd-l1 inhibitor cotherapy
JP6231129B2 (ja) 2013-01-10 2017-11-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 脂肪酸シンターゼ阻害剤
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
JP2016539149A (ja) 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
SI3101032T1 (sl) 2014-01-31 2019-02-28 Daiichi Sankyo Company, Limited Konjugat zdravila s protitelesci ANTI-HER2
EP3111222A1 (en) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
KR102561695B1 (ko) 2014-03-14 2023-07-28 제넨테크, 인크. 이형 폴리펩티드의 분비를 위한 방법 및 조성물
KR20160143808A (ko) 2014-04-11 2016-12-14 메디뮨 엘엘씨 이중특이적 her2 항체
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
MA40459A (fr) 2014-09-19 2016-03-24 Siwa Corp Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
CA2984458A1 (en) 2015-05-13 2016-11-17 Zymeworks Inc. Antigen-binding constructs targeting her2
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
AU2016336959A1 (en) * 2015-10-13 2018-04-12 Siwa Corporation Anti-age antibodies and methods of use thereof
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
RU2018123717A (ru) 2015-12-01 2020-01-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Комбинированные лечения, их применения и способы
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
CA3011949A1 (en) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN109476744B (zh) * 2016-05-12 2023-04-11 新加坡科技研究局 抗erbb-2抗体及其用途
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3524267A4 (en) 2016-10-07 2020-06-10 Daiichi Sankyo Company, Limited THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
EP3565845A4 (en) * 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
AU2018237359B2 (en) 2017-03-22 2024-06-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
CA3073383C (en) 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
KR20250105480A (ko) 2018-05-28 2025-07-08 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
AU2019309913B2 (en) 2018-07-23 2025-02-27 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
WO2020022363A1 (ja) 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
CN112805036A (zh) 2018-07-31 2021-05-14 第一三共株式会社 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
EP3834843A4 (en) 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
US12312641B2 (en) 2018-08-23 2025-05-27 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
JP7619938B2 (ja) 2018-09-25 2025-01-22 エイビーエスシーアイ・コーポレーション タンパク質精製方法
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
EA202191641A1 (ru) 2018-12-11 2021-09-13 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
MX2021007260A (es) 2018-12-19 2021-09-08 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
EP3917964A1 (en) 2019-02-01 2021-12-08 GlaxoSmithKline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
AU2020308053A1 (en) 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
AU2021206252A1 (en) 2020-01-10 2022-07-28 Trevi Therapeutics, Inc. Methods of administering nalbuphine
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
KR20220144821A (ko) 2020-02-21 2022-10-27 마크로제닉스, 인크. Cd137 결합 분자 및 그것의 용도
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd A combination of an antibody-drug conjugate and an ATR inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
TW202216207A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及cdk9抑制劑之組合
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
KR20230042055A (ko) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
KR20230084163A (ko) 2020-10-09 2023-06-12 아스트라제네카 유케이 리미티드 항체-약물 접합체와 parp1 선택적 억제제의 조합
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
AU2022401024A1 (en) 2021-11-30 2024-05-16 Daiichi Sankyo Company, Limited Protease-cleavable masked antibodies
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
EP4477674A1 (en) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
CA3249707A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
EP4522658A1 (en) 2022-05-11 2025-03-19 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
CA2207869A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
CN101412758A (zh) * 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999019488A1 (en) 1997-10-15 1999-04-22 Children's Medical Center Corporation Novel human egf receptors and use thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
AU782325B2 (en) * 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
MXPA01013395A (es) * 1999-06-25 2003-09-04 Genentech Inc Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
BRPI0012198B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc anticorpos humanizados, composição e imunoconjugado
KR20020012292A (ko) * 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
EP2110138A1 (en) * 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087260B2 (en) 2013-11-19 2018-10-02 Remegen, Ltd. Anti-HER2 antibody and conjugate thereof

Also Published As

Publication number Publication date
DK1189641T5 (da) 2011-04-11
WO2001000245A3 (en) 2001-10-25
RU2270029C2 (ru) 2006-02-20
AT500848B1 (de) 2008-01-15
CH694589A5 (de) 2005-04-15
KR20070094993A (ko) 2007-09-27
AU784045B2 (en) 2006-01-19
KR100797308B1 (ko) 2008-01-23
EP1189641B1 (en) 2009-07-29
NO2013005I2 (no) 2013-03-12
AU5763200A (en) 2001-01-31
AR024464A1 (es) 2002-10-02
FR13C0016I1 (cg-RX-API-DMAC7.html) 2013-04-12
PT1189641E (pt) 2009-11-04
ZA200110263B (en) 2003-02-26
DE10084743T1 (de) 2002-08-14
AU2005242195B2 (en) 2009-06-11
CN101518653A (zh) 2009-09-02
KR20020068264A (ko) 2002-08-27
ES2329437T3 (es) 2009-11-26
TR200103756T2 (tr) 2002-06-21
PL203326B1 (pl) 2009-09-30
CN101121021B (zh) 2011-12-07
EP2112167A2 (en) 2009-10-28
CY2013010I2 (el) 2015-08-05
GB0200506D0 (en) 2002-02-27
KR100850389B1 (ko) 2008-08-04
CZ299702B6 (cs) 2008-10-22
JP4283474B2 (ja) 2009-06-24
DE60042648D1 (de) 2009-09-10
BE2013C020I2 (cg-RX-API-DMAC7.html) 2019-08-21
BR122014028365B8 (pt) 2021-07-06
GEP20104998B (en) 2010-06-10
CZ20014596A3 (cs) 2003-02-12
HU226742B1 (en) 2009-08-28
JP2009142280A (ja) 2009-07-02
MXPA01013458A (es) 2002-07-30
CN101121021A (zh) 2008-02-13
CN101518653B (zh) 2015-08-19
AT500848A1 (de) 2006-04-15
NO20091792L (no) 2002-02-25
RU2430739C9 (ru) 2015-12-20
EP1189641A2 (en) 2002-03-27
NZ516830A (en) 2004-07-30
SI2283867T1 (sl) 2014-07-31
CY1109525T1 (el) 2014-08-13
RU2005132788A (ru) 2007-04-27
NO336040B1 (no) 2015-04-27
HUP0201695A2 (en) 2002-09-28
DK1189641T3 (da) 2009-11-16
BRPI0012198B8 (pt) 2021-05-25
CA2376596A1 (en) 2001-01-04
LU92164I2 (fr) 2013-05-07
RU2430739C2 (ru) 2011-10-10
NO20016329D0 (no) 2001-12-21
IL197359A0 (en) 2011-07-31
IL146954A (en) 2009-09-22
ZA200109786B (en) 2002-11-28
NO2013005I1 (no) 2013-04-02
HK1044888A1 (en) 2002-11-08
HUP0201695A3 (en) 2005-06-28
IL146954A0 (en) 2002-08-14
CN101121750A (zh) 2008-02-13
CN1370082A (zh) 2002-09-18
PL352321A1 (en) 2003-08-11
BRPI0012198B1 (pt) 2016-12-20
FR13C0016I2 (fr) 2014-05-16
PL204629B1 (pl) 2010-01-29
BR0012198A (pt) 2002-04-02
NZ531426A (en) 2005-10-28
CN100340575C (zh) 2007-10-03
SI2283866T1 (sl) 2015-07-31
GB2368796B (en) 2004-08-04
BR122014028365B1 (pt) 2020-01-28
EP2112167A3 (en) 2010-12-22
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
CY2013010I1 (el) 2015-08-05
AU2005242195A1 (en) 2006-01-12
WO2001000245A2 (en) 2001-01-04
SI1189641T1 (sl) 2009-12-31
CA2727172A1 (en) 2001-01-04
ATE437655T1 (de) 2009-08-15
JP2003503366A (ja) 2003-01-28
GB2368796A (en) 2002-05-15

Similar Documents

Publication Publication Date Title
CA2376596C (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US7618631B2 (en) Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
CA2383493C (en) Treating prostate cancer with anti-erbb2 antibodies
US20040013667A1 (en) Treatment with anti-ErbB2 antibodies
US20070184055A1 (en) Treatment with anti-erbb2 antibodies
US7041292B1 (en) Treating prostate cancer with anti-ErbB2 antibodies
AU2005232657A1 (en) ErbB antagonists for pain therapy
HK1130502A (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
HK1044888B (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
EEER Examination request